Search for: "FTC v. Boehringer Ingelheim Pharm." Results 1 - 2 of 2
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
FDA/FTC Workshop on a Competitive Marketplace for Biosimilars
9 Mar 2020, 1:21 pm by Unknown
   · Molly Burich, Director of Public Policy, Boehringer Ingelheim   · Surya Singh, President, Singh Healthcare Advisors, LLC  Moderated Panel Discussion  Meredyth Andrus, Attorney, Health Care Division, Bureau of Competition, FTC Does the designation of interchangeability still have value in the US? [read post]
43(B)log - http://tushnet.blogspot.com/
IP Think Tank Global Week in Review - 29 February 2008
29 Feb 2008, 8:00 am
– Teva’s opposition proceedings regarding IL 130424 to Pfizer: (IP Factor), Thailand: Thai chief drug price negotiator removed from post: (GenericsWeb), Thailand: Compulsory licences cannot be revoked: (Generic Pharmaceuticals & IP), (more from Generic Pharmaceuticals & IP), UK: Court of Appeal for England and Wales hands down decision in Boehringer Ingelheim KG and Boehringer Ingelheim Pharma KG v Swingward Limited… [read post]
IP Thinktank - http://duncanbucknell.com/ipthinktank.blog